(Q54392190)

English

High-level ERBB2 gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24311197

High-level ERBB2 gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting. (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24311197

Erb-b2 receptor tyrosine kinase 2

1 reference

based on heuristic

inferred from title

author name string

Eva-Maria Fuchs

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311197%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Wolfgang J Köstler

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311197%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Reinhard Horvat

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311197%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Gernot Hudelist

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311197%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Ernst Kubista

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311197%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Christoph C Zielinski

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311197%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

0 references

publication date

28 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24311197

number of pages

8

1 reference

based on heuristic

inferred from page(s)

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311197%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

135

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311197%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311197%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

224-231

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311197%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28660

21 January 2018

Co-Expression of ErbB-Family Members in Human Breast Cancer: Her-2/neu is the Preferred Dimerization Candidate in Nodal-positive Tumors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28660

21 January 2018

The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28660

21 January 2018

Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28660

21 January 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28660

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28660

21 January 2018

Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28660

21 January 2018

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28660

21 January 2018

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28660

21 January 2018

HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28660

21 January 2018

Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28660

21 January 2018

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28660

21 January 2018

Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28660

21 January 2018

Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28660

21 January 2018

Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28660

21 January 2018

In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28660

21 January 2018

Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28660

21 January 2018

Identifiers

10.1002/IJC.28660

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311197%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311197%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54392190&oldid=2270411836"